Imagine if you could check your blood sugar just by breathing into a small device, similar to how a breathalyzer works. It mimics a dog's incredible sense of smell to detect specific chemicals in your breath that reveal your glucose levels. This means no more painful finger-pricking or expensive disposable strips.
Current blood glucose monitoring is invasive, expensive, and stigmatising, leading to underuse by patients. This results in poorer diabetes management and higher long-term healthcare costs.
A pocket-size breath analyser using a Gas Sensor Array and an embedded algorithm to calculate blood glucose from Volatile Organic Compounds.
If you are a hardware developer dealing with the high cost and waste of disposable glucose strips — this project developed a pocket-size breath analyser that requires no consumables. It provides a painless alternative to finger-pricking for 40 million people in Europe.
If you are a clinic dealing with low patient compliance due to invasive testing — this project developed a device that takes less than 2 minutes to measure glucose via breath. This leads to more frequent testing and better diabetes management.
If you are an app developer dealing with a lack of non-invasive data sources for diabetes — this project developed a system where breath analysis results are shared via third party Mobile App platforms. This integrates painless monitoring into the digital health ecosystem.
The device is cost-effective because it operates without any consumables, eliminating the need for expensive disposable strips used in traditional meters.
Based on available project data, the EIC Accelerator grant has allowed the company to finalise product development and validation, moving toward a pocket-size commercial version.
Based on available project data, the technology uses a Gas Sensor Array and an embedded algorithm validated through three clinical trials, though specific patent numbers are not listed.
The analysis takes less than 2 minutes to measure Volatile Organic Compounds in exhaled breath.
The results are shared between patients and healthcare professionals through third party Mobile App platforms.
The project is led by a single French SME, BOYDSense, which holds 100% of the industry ratio. This lean structure indicates that the intellectual property and commercial control remain centralized within the coordinating company, reducing coordination overhead for the EIC Accelerator grant.
Contact BOYDSense in France for licensing or partnership opportunities regarding the Lassie device.
Contact us to find similar non-invasive diagnostic technologies for chronic disease management.
